A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer

Completed · Phase 2 · Has a placebo group

Conditions studied: Pancreatic Cancer

In brief

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.

Key facts

Study ID

NCT00055250

Run by

Eli Lilly and Company

People needed

130

Starts

2003-01-01

Expected to finish

2005-10-01

Last updated by the study team

2007-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adenocarcinoma of the pancreas that is locally advanced or metastatic and not amenable to resection with curative intent
• Tumor that can be measured by x-ray or scan
• Adequate organ function

You may not qualify if…

• Inability to swallow capsules
• Documented brain metastases
• Prior chemotherapy or biological therapy for this disease

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5pm Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician. — Lakeland, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.